Cyanidin prevents MDPV withdrawal-induced anxiety-like effects and dysregulation of cytokine systems in rats

[1]  Zichen Ye,et al.  Cyanidin Chloride Improves LPS-Induced Depression-Like Behavior in Mice by Ameliorating Hippocampal Inflammation and Excitotoxicity. , 2022, ACS chemical neuroscience.

[2]  T. Eisenstein,et al.  Purinergic P2X7 receptor antagonist inhibits methamphetamine-induced reward, hyperlocomotion, and cortical IL-7A levels in mice: A role for P2X7/IL-17A crosstalk in methamphetamine behaviors? , 2022, Brain, Behavior, and Immunity.

[3]  M. Wimmer,et al.  Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats. , 2022, Drug and alcohol dependence.

[4]  B. McCool,et al.  Chronic Alcohol Dysregulates Glutamatergic Function in the Basolateral Amygdala in a Projection-and Sex-Specific Manner , 2022, Frontiers in Cellular Neuroscience.

[5]  E. Nestler,et al.  Midbrain projection to the basolateral amygdala encodes anxiety-like but not depression-like behaviors , 2022, Nature Communications.

[6]  Kevin T. Beier,et al.  An extended amygdala-midbrain circuit controlling cocaine withdrawal-induced anxiety and reinstatement , 2021, bioRxiv.

[7]  A. Reitz,et al.  Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonist. , 2021, Drug and alcohol dependence.

[8]  B. Blough,et al.  Sex differences in inflammatory cytokine levels following synthetic cathinone self-administration in rats. , 2021, Neurotoxicology.

[9]  P. Kulkarni,et al.  The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats , 2021, Journal of psychiatry & neuroscience : JPN.

[10]  W. J. Lynch,et al.  The importance of examining sex differences in animal models validated to induce an addiction-like phenotype , 2021, Pharmacology Biochemistry and Behavior.

[11]  Y. Sari,et al.  Ceftriaxone Reduces Waterpipe Tobacco Smoke Withdrawal-induced Anxiety in rats via Modulating the Expression of TNF-α/NFĸB, Nrf2, and GLT-1 , 2021, Neuroscience.

[12]  S. Ikemoto,et al.  Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review , 2021, Pharmacological Reviews.

[13]  C. Gipson,et al.  Interactions of neuroimmune signaling and glutamate plasticity in addiction , 2021, Journal of neuroinflammation.

[14]  Y. Suh,et al.  Interleukin-17 induced by cumulative mild stress promoted depression-like behaviors in young adult mice , 2021, Molecular brain.

[15]  G. Smith,et al.  Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders , 2020, JAMA psychiatry.

[16]  L. Fattore,et al.  Sex and Gender Differences in the Effects of Novel Psychoactive Substances , 2020, Brain sciences.

[17]  Jasmin Herz,et al.  Meningeal γδ T cells regulate anxiety-like behavior via IL-17a signaling in neurons , 2020, Biological Psychiatry.

[18]  Qinan Wu,et al.  Cyanidin-related antidepressant-like efficacy requires PI3K/AKT/FoxG1/FGF-2 pathway modulated enhancement of neuronal differentiation and dendritic maturation. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[19]  L. Taams.  Interleukin-17 in rheumatoid arthritis: Trials and tribulations , 2020, The Journal of experimental medicine.

[20]  S. Rawls,et al.  Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist , 2020, Brain, Behavior, and Immunity.

[21]  B. Becher,et al.  Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective , 2019, The Journal of experimental medicine.

[22]  C. Ehlers,et al.  Time course of blood and brain cytokine/chemokine levels following adolescent alcohol exposure and withdrawal in rats. , 2019, Alcoholism, clinical and experimental research.

[23]  S. Gaffen,et al.  IL-17 receptor–based signaling and implications for disease , 2019, Nature Immunology.

[24]  S. Maier,et al.  Methamphetamine activates Toll-like receptor 4 to induce central immune signaling within the ventral tegmental area and contributes to extracellular dopamine increase in the nucleus accumbens shell. , 2019, ACS chemical neuroscience.

[25]  Ya-Chi Li,et al.  Interleukin‐6 and interleukin‐17 are related to depression in patients with rheumatoid arthritis , 2019, International journal of rheumatic diseases.

[26]  P. Kalivas,et al.  Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core , 2019, Neuroscience.

[27]  M. Farzaei,et al.  Anthocyanins in the Management of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review , 2018, Front. Pharmacol..

[28]  S. Matsuzaki,et al.  Chemokine CXCL1 is responsible for cocaine‐induced reward in mice , 2018, Neuropsychopharmacology reports.

[29]  S. J. Simmons,et al.  Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. , 2018, Drug and alcohol dependence.

[30]  A. Suksamrarn,et al.  Cyanidin attenuates Aβ25-35-induced neuroinflammation by suppressing NF-κB activity downstream of TLR4/NOX4 in human neuroblastoma cells , 2018, Acta Pharmacologica Sinica.

[31]  L. Liu-Chen,et al.  Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. , 2018, ACS chemical neuroscience.

[32]  S. Matsuzaki,et al.  Upregulation of CCL7 and CCL2 in reward system mediated through dopamine D1 receptor signaling underlies methamphetamine-induced place preference in mice , 2018, Neuroscience Letters.

[33]  L. Watkins,et al.  Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking , 2018, Brain, Behavior, and Immunity.

[34]  S. Comer,et al.  Glial and neuroinflammatory targets for treating substance use disorders. , 2017, Drug and alcohol dependence.

[35]  L. Liu-Chen,et al.  Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats. , 2017, Drug and alcohol dependence.

[36]  P. Kalivas,et al.  Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse , 2017, The international journal of neuropsychopharmacology.

[37]  E. Unterwald,et al.  Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats , 2017, Brain, Behavior, and Immunity.

[38]  J. González‐Gallego,et al.  Protective Effect of Protocatechuic Acid on TNBS-Induced Colitis in Mice Is Associated with Modulation of the SphK/S1P Signaling Pathway , 2017, Nutrients.

[39]  J. Qin,et al.  The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo , 2017, Science Signaling.

[40]  A. Reitz,et al.  Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator , 2016, Neuropharmacology.

[41]  B. Kieffer,et al.  Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction , 2016, The international journal of neuropsychopharmacology.

[42]  N. Kiguchi,et al.  [The role of CC-chemokine ligand 2 in the development of psychic dependence on methamphetamine]. , 2015, Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.

[43]  R. Pandey,et al.  Serum cytokines and anxiety in adolescent depression patients: Gender effect , 2015, Psychiatry Research.

[44]  S. Maier,et al.  Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4. , 2015, CNS & neurological disorders drug targets.

[45]  D. Pow,et al.  GLAST But Not Least—Distribution, Function, Genetics and Epigenetics of l-Glutamate Transport in Brain—Focus on GLAST/EAAT1 , 2015, Neurochemical Research.

[46]  J. Lépine,et al.  Anxiety and Substance Use Disorders: Co-occurrence and Clinical Issues , 2015, Current Psychiatry Reports.

[47]  L. Aurelian,et al.  CRF-Amplified Neuronal TLR4/MCP-1 Signaling Regulates Alcohol Self-Administration , 2015, Neuropsychopharmacology.

[48]  S. Yoon,et al.  Cyanidin-3-glucoside Inhibits ATP-induced Intracellular Free Ca2+ Concentration, ROS Formation and Mitochondrial Depolarization in PC12 Cells , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[49]  N. Kiguchi,et al.  CC-chemokine ligand 2 facilitates conditioned place preference to methamphetamine through the activation of dopamine systems. , 2014, Journal of pharmacological sciences.

[50]  S. Janković,et al.  Antioxidant and anxiolytic activities of Crataegus nigra Wald. et Kit. berries. , 2014, Acta poloniae pharmaceutica.

[51]  I. Mocchetti,et al.  CCL5 and cytokine expression in the rat brain: Differential modulation by chronic morphine and morphine withdrawal , 2013, Brain, Behavior, and Immunity.

[52]  A. Karson,et al.  Effects of long-term etanercept treatment on anxiety- and depression-like neurobehaviors in rats , 2013, Physiology & Behavior.

[53]  Jun Chen,et al.  The contribution of TNF-α in the amygdala to anxiety in mice with persistent inflammatory pain , 2013, Neuroscience Letters.

[54]  Alice M Stamatakis,et al.  Distinct extended amygdala circuits for divergent motivational states , 2013, Nature.

[55]  Kurt R. Lehner,et al.  Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products , 2013, Neuropsychopharmacology.

[56]  M. Liechti,et al.  Pharmacological characterization of designer cathinones in vitro , 2013, British journal of pharmacology.

[57]  D. Centonze,et al.  TNF-α-mediated anxiety in a mouse model of multiple sclerosis , 2012, Experimental Neurology.

[58]  Patrice D Cani,et al.  Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects , 2012, Brain, Behavior, and Immunity.

[59]  M. Solas,et al.  Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus , 2012, Neuropharmacology.

[60]  R. Ho,et al.  The role of interleukin (IL)‐17 in anxiety and depression of patients with rheumatoid arthritis , 2012, International journal of rheumatic diseases.

[61]  C. Vorhees,et al.  Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague–Dawley rats: Effects of anxiolytic and anxiogenic agents , 2011, Pharmacology Biochemistry and Behavior.

[62]  R. Andrade,et al.  Enhanced Th17 phenotype in individuals with generalized anxiety disorder , 2010, Journal of Neuroimmunology.

[63]  Qing-hui Zhou,et al.  Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. , 2010, Journal of biotechnology.

[64]  S. Gaffen,et al.  Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease , 2010, Immunology.

[65]  P. Kalivas,et al.  Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking , 2010, Biological Psychiatry.

[66]  R. LaLumiere,et al.  Glutamate transmission in addiction , 2009, Neuropharmacology.

[67]  L. Boulanger,et al.  Immune Proteins in Brain Development and Synaptic Plasticity , 2009, Neuron.

[68]  P. Kalivas.  The glutamate homeostasis hypothesis of addiction , 2009, Nature Reviews Neuroscience.

[69]  R. Colbran,et al.  Alcohol Exposure Alters NMDAR Function in the Bed Nucleus of the Stria Terminalis , 2009, Neuropsychopharmacology.

[70]  E. Unterwald,et al.  Modulation of cocaine-induced activity by intracerebral administration of CXCL12 , 2009, Neuroscience.

[71]  P. Kalivas,et al.  The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans , 2009, Biological Psychiatry.

[72]  M. Filip,et al.  Immunosuppression induced by a conditioned stimulus associated with cocaine self-administration. , 2008, Journal of pharmacological sciences.

[73]  H. Schiöth,et al.  Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats , 2008, BMC Neuroscience.

[74]  F. Crews,et al.  Increased MCP-1 and microglia in various regions of the human alcoholic brain , 2008, Experimental Neurology.

[75]  S. Gaffen,et al.  Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. , 2008, Cytokine.

[76]  T. Hyphantis,et al.  Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[77]  J. Derry,et al.  Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex , 2006, The Journal of Immunology.

[78]  S. Bergeson,et al.  Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol , 2005, Behavioural Brain Research.

[79]  S. Geisler,et al.  Afferents of the ventral tegmental area in the rat‐anatomical substratum for integrative functions , 2005, The Journal of comparative neurology.

[80]  B. McEwen,et al.  Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P. Kalivas,et al.  Prefrontal Glutamate Release into the Core of the Nucleus Accumbens Mediates Cocaine-Induced Reinstatement of Drug-Seeking Behavior , 2003, The Journal of Neuroscience.

[82]  Paine Ta,et al.  Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. , 2002 .

[83]  G. Aston-Jones,et al.  Potent Regulation of Midbrain Dopamine Neurons by the Bed Nucleus of the Stria Terminalis , 2001, The Journal of Neuroscience.

[84]  D. Blanchard,et al.  Cocaine potentiates defensive behaviors related to fear and anxiety , 1999, Neuroscience & Biobehavioral Reviews.

[85]  G. Koob,et al.  Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like” effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats , 1999, Psychopharmacology.

[86]  Z. Sarnyai,et al.  Brain corticotropin-releasing factor mediates ‘anxiety-like’ behavior induced by cocaine withdrawal in rats , 1995, Brain Research.

[87]  Theadia L Carey.  Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders. , 2019, Handbook of experimental pharmacology.

[88]  C. Grillon,et al.  Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety , 2010, Neuropsychopharmacology.

[89]  G. Aston-Jones,et al.  β-adrenergic antagonists attenuate withdrawal anxiety in cocaine-and morphine-dependent rats , 2005, Psychopharmacology.